6p22.3 amplification as a biomarker and potential therapeutic target of advanced stage bladder cancer

He Shen, Carl D. Morrison, Jianmin Zhang, Willie Underwood, Nuo Yang, Costa Frangou, Kevin Eng, Karen Head, Roni Jacob Bollag, Sravan Kumar Kavuri, Amyn Mohammed Rojiani, Yingwei Li, Li Yan, Annette Hill, Anna Woloszynska-Read, Jianmin Wang, Song Liu, Donald L. Trump, Johnson S. Candace

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Genetic and epigenetic alterations have been identified as to contribute directly or indirectly to the generation of transitional cell carcinoma of the urinary bladder (TCC-UB). In a comparative fashion much less is known about copy number alterations in TCC-UB, but it appears that amplification of chromosome 6p22 is one of the most frequent changes. Using fluorescence in situ hybridization (FISH) analyses, we evaluated chromosomal 6p22 amplification in a large cohort of bladder cancer patients with complete surgical staging and outcome data. We have also used shRNA knockdown candidate oncogenes in the cell based study. We found that amplification of chromosome 6p22.3 is significantly associated with the muscle-invasive transitional cell carcinoma of the urinary bladder (TCC-UB) (22%) in contrast to superficial TCC-UB (9%) (p=7.2-04). The rate of 6p22.3 amplification in pN>1 patients (32%) is more than twice that in pN0 (16%) patients (p=0.05). Interestingly, we found that 6p22.3 amplification is as twice as high (p=0.0201) in African American (AA) than European American (EA) TCC-UB patients. Moreover, we showed that the expression of some candidate genes (E2F3, CDKAL1 and Sox4) in the 6p22.3 region is highly correlated with the chromosomal amplification. In particular, knockdown of E2F3 inhibits cell proliferation in a 6p22.3-dependent manner, whereas knockdown of CDKAL1 and Sox4 has no effect on cell proliferation. Using gene expression profiling, we further identified some common as well as distinctive subset targets of the E2F3 family members. In summary, our data indicate that E2F3 is a key regulator of cell proliferation in a subset of bladder cancer and the 6p22.3 amplicon is a biomarker of aggressive phenotype in this tumor type.

Original languageEnglish (US)
Pages (from-to)2124-2134
Number of pages11
JournalOncotarget
Volume4
Issue number11
DOIs
StatePublished - Jan 1 2013

Fingerprint

Transitional Cell Carcinoma
Urinary Bladder Neoplasms
Urinary Bladder
Biomarkers
Cell Proliferation
Chromosomes
Therapeutics
Gene Expression Profiling
Fluorescence In Situ Hybridization
Oncogenes
Epigenomics
African Americans
Small Interfering RNA
Phenotype
Muscles
Genes
Neoplasms

Keywords

  • Bladder cancer
  • Chromosome 6p22
  • FISH
  • Outcome
  • Survival

ASJC Scopus subject areas

  • Oncology

Cite this

Shen, H., Morrison, C. D., Zhang, J., Underwood, W., Yang, N., Frangou, C., ... Candace, J. S. (2013). 6p22.3 amplification as a biomarker and potential therapeutic target of advanced stage bladder cancer. Oncotarget, 4(11), 2124-2134. https://doi.org/10.18632/oncotarget.1485

6p22.3 amplification as a biomarker and potential therapeutic target of advanced stage bladder cancer. / Shen, He; Morrison, Carl D.; Zhang, Jianmin; Underwood, Willie; Yang, Nuo; Frangou, Costa; Eng, Kevin; Head, Karen; Bollag, Roni Jacob; Kavuri, Sravan Kumar; Rojiani, Amyn Mohammed; Li, Yingwei; Yan, Li; Hill, Annette; Woloszynska-Read, Anna; Wang, Jianmin; Liu, Song; Trump, Donald L.; Candace, Johnson S.

In: Oncotarget, Vol. 4, No. 11, 01.01.2013, p. 2124-2134.

Research output: Contribution to journalArticle

Shen, H, Morrison, CD, Zhang, J, Underwood, W, Yang, N, Frangou, C, Eng, K, Head, K, Bollag, RJ, Kavuri, SK, Rojiani, AM, Li, Y, Yan, L, Hill, A, Woloszynska-Read, A, Wang, J, Liu, S, Trump, DL & Candace, JS 2013, '6p22.3 amplification as a biomarker and potential therapeutic target of advanced stage bladder cancer', Oncotarget, vol. 4, no. 11, pp. 2124-2134. https://doi.org/10.18632/oncotarget.1485
Shen, He ; Morrison, Carl D. ; Zhang, Jianmin ; Underwood, Willie ; Yang, Nuo ; Frangou, Costa ; Eng, Kevin ; Head, Karen ; Bollag, Roni Jacob ; Kavuri, Sravan Kumar ; Rojiani, Amyn Mohammed ; Li, Yingwei ; Yan, Li ; Hill, Annette ; Woloszynska-Read, Anna ; Wang, Jianmin ; Liu, Song ; Trump, Donald L. ; Candace, Johnson S. / 6p22.3 amplification as a biomarker and potential therapeutic target of advanced stage bladder cancer. In: Oncotarget. 2013 ; Vol. 4, No. 11. pp. 2124-2134.
@article{c4e60e2f3f7c414381046dee9016ee34,
title = "6p22.3 amplification as a biomarker and potential therapeutic target of advanced stage bladder cancer",
abstract = "Genetic and epigenetic alterations have been identified as to contribute directly or indirectly to the generation of transitional cell carcinoma of the urinary bladder (TCC-UB). In a comparative fashion much less is known about copy number alterations in TCC-UB, but it appears that amplification of chromosome 6p22 is one of the most frequent changes. Using fluorescence in situ hybridization (FISH) analyses, we evaluated chromosomal 6p22 amplification in a large cohort of bladder cancer patients with complete surgical staging and outcome data. We have also used shRNA knockdown candidate oncogenes in the cell based study. We found that amplification of chromosome 6p22.3 is significantly associated with the muscle-invasive transitional cell carcinoma of the urinary bladder (TCC-UB) (22{\%}) in contrast to superficial TCC-UB (9{\%}) (p=7.2-04). The rate of 6p22.3 amplification in pN>1 patients (32{\%}) is more than twice that in pN0 (16{\%}) patients (p=0.05). Interestingly, we found that 6p22.3 amplification is as twice as high (p=0.0201) in African American (AA) than European American (EA) TCC-UB patients. Moreover, we showed that the expression of some candidate genes (E2F3, CDKAL1 and Sox4) in the 6p22.3 region is highly correlated with the chromosomal amplification. In particular, knockdown of E2F3 inhibits cell proliferation in a 6p22.3-dependent manner, whereas knockdown of CDKAL1 and Sox4 has no effect on cell proliferation. Using gene expression profiling, we further identified some common as well as distinctive subset targets of the E2F3 family members. In summary, our data indicate that E2F3 is a key regulator of cell proliferation in a subset of bladder cancer and the 6p22.3 amplicon is a biomarker of aggressive phenotype in this tumor type.",
keywords = "Bladder cancer, Chromosome 6p22, FISH, Outcome, Survival",
author = "He Shen and Morrison, {Carl D.} and Jianmin Zhang and Willie Underwood and Nuo Yang and Costa Frangou and Kevin Eng and Karen Head and Bollag, {Roni Jacob} and Kavuri, {Sravan Kumar} and Rojiani, {Amyn Mohammed} and Yingwei Li and Li Yan and Annette Hill and Anna Woloszynska-Read and Jianmin Wang and Song Liu and Trump, {Donald L.} and Candace, {Johnson S.}",
year = "2013",
month = "1",
day = "1",
doi = "10.18632/oncotarget.1485",
language = "English (US)",
volume = "4",
pages = "2124--2134",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "11",

}

TY - JOUR

T1 - 6p22.3 amplification as a biomarker and potential therapeutic target of advanced stage bladder cancer

AU - Shen, He

AU - Morrison, Carl D.

AU - Zhang, Jianmin

AU - Underwood, Willie

AU - Yang, Nuo

AU - Frangou, Costa

AU - Eng, Kevin

AU - Head, Karen

AU - Bollag, Roni Jacob

AU - Kavuri, Sravan Kumar

AU - Rojiani, Amyn Mohammed

AU - Li, Yingwei

AU - Yan, Li

AU - Hill, Annette

AU - Woloszynska-Read, Anna

AU - Wang, Jianmin

AU - Liu, Song

AU - Trump, Donald L.

AU - Candace, Johnson S.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Genetic and epigenetic alterations have been identified as to contribute directly or indirectly to the generation of transitional cell carcinoma of the urinary bladder (TCC-UB). In a comparative fashion much less is known about copy number alterations in TCC-UB, but it appears that amplification of chromosome 6p22 is one of the most frequent changes. Using fluorescence in situ hybridization (FISH) analyses, we evaluated chromosomal 6p22 amplification in a large cohort of bladder cancer patients with complete surgical staging and outcome data. We have also used shRNA knockdown candidate oncogenes in the cell based study. We found that amplification of chromosome 6p22.3 is significantly associated with the muscle-invasive transitional cell carcinoma of the urinary bladder (TCC-UB) (22%) in contrast to superficial TCC-UB (9%) (p=7.2-04). The rate of 6p22.3 amplification in pN>1 patients (32%) is more than twice that in pN0 (16%) patients (p=0.05). Interestingly, we found that 6p22.3 amplification is as twice as high (p=0.0201) in African American (AA) than European American (EA) TCC-UB patients. Moreover, we showed that the expression of some candidate genes (E2F3, CDKAL1 and Sox4) in the 6p22.3 region is highly correlated with the chromosomal amplification. In particular, knockdown of E2F3 inhibits cell proliferation in a 6p22.3-dependent manner, whereas knockdown of CDKAL1 and Sox4 has no effect on cell proliferation. Using gene expression profiling, we further identified some common as well as distinctive subset targets of the E2F3 family members. In summary, our data indicate that E2F3 is a key regulator of cell proliferation in a subset of bladder cancer and the 6p22.3 amplicon is a biomarker of aggressive phenotype in this tumor type.

AB - Genetic and epigenetic alterations have been identified as to contribute directly or indirectly to the generation of transitional cell carcinoma of the urinary bladder (TCC-UB). In a comparative fashion much less is known about copy number alterations in TCC-UB, but it appears that amplification of chromosome 6p22 is one of the most frequent changes. Using fluorescence in situ hybridization (FISH) analyses, we evaluated chromosomal 6p22 amplification in a large cohort of bladder cancer patients with complete surgical staging and outcome data. We have also used shRNA knockdown candidate oncogenes in the cell based study. We found that amplification of chromosome 6p22.3 is significantly associated with the muscle-invasive transitional cell carcinoma of the urinary bladder (TCC-UB) (22%) in contrast to superficial TCC-UB (9%) (p=7.2-04). The rate of 6p22.3 amplification in pN>1 patients (32%) is more than twice that in pN0 (16%) patients (p=0.05). Interestingly, we found that 6p22.3 amplification is as twice as high (p=0.0201) in African American (AA) than European American (EA) TCC-UB patients. Moreover, we showed that the expression of some candidate genes (E2F3, CDKAL1 and Sox4) in the 6p22.3 region is highly correlated with the chromosomal amplification. In particular, knockdown of E2F3 inhibits cell proliferation in a 6p22.3-dependent manner, whereas knockdown of CDKAL1 and Sox4 has no effect on cell proliferation. Using gene expression profiling, we further identified some common as well as distinctive subset targets of the E2F3 family members. In summary, our data indicate that E2F3 is a key regulator of cell proliferation in a subset of bladder cancer and the 6p22.3 amplicon is a biomarker of aggressive phenotype in this tumor type.

KW - Bladder cancer

KW - Chromosome 6p22

KW - FISH

KW - Outcome

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84890134222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890134222&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.1485

DO - 10.18632/oncotarget.1485

M3 - Article

C2 - 24231253

AN - SCOPUS:84890134222

VL - 4

SP - 2124

EP - 2134

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 11

ER -